Nalaganje...
Converting lymphoma cells into potent antigen-presenting cells for interferon-induced tumor regression
Anti-hCD20 is a therapeutic monoclonal antibody (mAb) that is clinically used to treat B-cell lymphoma. Some lymphomas are resistant to anti-hCD20; others relapse after treatment with anti-hCD20. Using a syngeneic immunocompetent mouse model, we observed that targeting lymphoma with interferon-α (IF...
Shranjeno v:
| izdano v: | Cancer Immunol Res |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5510552/ https://ncbi.nlm.nih.gov/pubmed/28533311 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-16-0221 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|